🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Aetion, Inc. has been named to NY Digital Health 100 by @digitalhealthny! We’re honored to be included among the top healthcare innovators in the NY region. See the full #DH100 list in the 2023 New York Healthcare Innovation Report: hubs.li/Q01zR40P0

Aetion, Inc. is pleased to announce our partnership with TREAT-NMD®, the leading global registry network focused on rare #neuromuscular diseases. We are united in our mission to advance treatments and better outcomes for #neuromuscular patients globally. hubs.li/Q01D4qBL0

Join @Nmahendraratnam, Sr. Dir. Real World Solutions Aetion, Inc., on Tues. 2/28 at 12 p.m. ET for FasterCures' discussion on building and sustaining diversity & equity in digital health. Register here: hubs.li/Q01Dx8Hh0.

Today, the final results of the RCT-DUPLICATE study were published, demonstrating the ability of #RWE studies to reach similar conclusions as randomized clinical trials when specific designs and measurements are replicated. Read more here: [hubs.li/Q01MJ2Jj0].

Today on the Aetion Evidence Hub, Aetion, Inc. scientists Liz Garry, Head of Scientific Research, and Liza Gibbs, Principal Scientist II, take us on a deep dive into RCT-DUPLICATE, the results of which were published this week in JAMA. Read the blog here: hubs.li/Q01MYCYt0

Next week at #ISPORAnnual, Aetion, Inc.'s Nirosha Lederer will speak on the panel, ‘Medicare Coverage with Evidence Development for Drugs Approved for Alzheimer’s Disease: Which Study Designs and Data Sources Would Best Answer Medicare’s Questions.’

Today at #ISPORAnnual, we are proud to launch Aetion® Discover—an application that provides users with an intuitive interface to generate swift hypotheses and insights across the biopharmaceutical and medtech lifecycle. Read more here: hubs.li/Q01NYDkl0. #RWD #RWE

Quick insights without cutting corners - that's Aetion® Discover. If you're interested in a demo of our new application that helps you define and understand populations, outcomes, treatments, and trends of interest - don’t hesitate to reach out: hubs.li/Q01NWrFm0.

Got tons of questions and even more data? We get it. Today Aetion, Inc. launched our new application, Discover, which serves up quick insights to meet your needs. Click to learn more: hubs.li/Q01NWt180.

The drug price negotiation provisions of the IRA are being implemented rapidly, and there are big implications for #RWE. Read more about Aetion's perspective on the future of price negotiations, and why the quality of the RWE will matter: hubs.li/Q01QfQfh0.

Aetion, Inc.'s work is the knowing, showing, and sharing of how medical innovations work. It’s an honor to see our #clients showcase how our technology - Aetion Evidence Platform® - is producing results/delivering better treatment options to patients: hubs.li/Q01QnnDr0.

On Wednesday, June 7, Aetion, Inc. CEO Carolyn Magill will take to the stage alongside fellow panelists Kate Condliffe, Darshak Sanghvi, and Christina Severin to discuss the promise and perils of innovation in Medicaid at #DHISEast in Boston: hubs.li/Q01RRwyP0.

In a recent article in Future Medicine AI, Ae Tion expert @Nmahendraratnam and co-author Yashoda Sharma (@_DiMeSociety) discuss the potential of #AI/ML to process valuable healthcare data and why it must be done with an eye toward #inclusivity and #diversity: hubs.li/Q01XXcWq0

xcures.com/xcures-contrib… Aetion, Inc. #realworlddata #CancerResearch #oncology

A new article from Clinical Leader feat. Shirley Wang published today, highlighting the Aetion Evidence Platform® & results from the RCT-DUPLICATE study. To learn how Aetion, Inc. is helping assess the benefits, limitations, & uses of #RWD, read more: hubs.li/Q01-31Y_0

Today in #CPTJournal, Ulka Campbell, Aetion, Inc.'s Head of Scientific Strategy, outlines #SURF—a tool that gives sponsors clear and practical guidance around the use of #RWE to support effectiveness claims. More here: hubs.li/Q020dLPf0.

With #SURF, sponsors have a tool that builds upon Aetion, Inc.’s years #RWE experience and to determine when an RWE approach for providing evidence of effectiveness in an application may be acceptable. Request a meeting with our experts: hubs.li/Q020dHYS0

Today on the Aetion, Inc. #EHub, our Head of Scientific Strategy, Ulka Campbell, discusses the publication of #SURF - a screening tool to help evaluate the regulatory feasibility of using #RWD to support an effectiveness claim in an FDA application: hubs.li/Q020y-pH0

Last week at #ICPE2023, our experts had their ears to the ground learning about the latest trends in #RWE! Hear what Jade Cusick, Chief Commerical Officer at Aetion, Inc. took away from his time onsite with the #ATeam, now live on our Evidence Hub: hubs.li/Q020VYhC0

WEBINAR: SURF screening tool to determine suitability of using real-world evidence – November 8, 2023 Aetion, Inc. evidencebaseonline.com/webinars/webin…